Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis.
暂无分享,去创建一个
S. Scott | G. Montalescot | J. Hulot | J. Collet | J. Silvain | F. Beygui | G. Cayla | A. Pathak | Y. Gruel | S. O’Connor | J. Vignalou | O. Barthelemy | Axel de la Briolle | Frédérick Allanic | Yves Huerre | S. Scott
[1] D. Mansuy,et al. Paraoxonase-1 and clopidogrel efficacy , 2011, Nature Medicine.
[2] P. Morange,et al. Paraoxonase-1 and clopidogrel efficacy , 2011, Nature Medicine.
[3] C. Hirschhäuser,et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy , 2011, Nature Medicine.
[4] M. Fromm,et al. Paraoxonase-1 Q192R Polymorphism and Antiplatelet Effects of Clopidogrel in Patients Undergoing Elective Coronary Stent Placement , 2011, Circulation. Cardiovascular genetics.
[5] A. Kastrati,et al. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. , 2011, European heart journal.
[6] J. Marchesini,et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. , 2011, Journal of the American College of Cardiology.
[7] G. Stone,et al. Frequency and Predictors of Stent Thrombosis After Percutaneous Coronary Intervention in Acute Myocardial Infarction , 2011, Circulation.
[8] G. Montalescot,et al. High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2). , 2011, JACC. Cardiovascular interventions.
[9] G. Patrinos,et al. Sequence variations in the FII, FV, F13A1, FGB and PAI-1 genes are associated with differences in myocardial perfusion. , 2011, Pharmacogenomics.
[10] L. Bergougnan,et al. Differential Effects of Omeprazole and Pantoprazole on the Pharmacodynamics and Pharmacokinetics of Clopidogrel in Healthy Subjects: Randomized, Placebo‐Controlled, Crossover Comparison Studies , 2011, Clinical pharmacology and therapeutics.
[11] S. Werns. Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes , 2011 .
[12] J. Mega,et al. Consortium ( CPIC ) guidelines for cytochrome P 450-2 C 19 ( CYP 2 C 19 ) genotype and clopidogrel therapy , 2011 .
[13] P. Barragan,et al. Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism. , 2010, Journal of the American College of Cardiology.
[14] E. Antman,et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. , 2010, JAMA.
[15] E. Antman,et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON–TIMI 38 trial: a pharmacogenetic analysis , 2010, The Lancet.
[16] B. J. Barratt,et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial , 2010, The Lancet.
[17] Volkmar Falk,et al. Guidelines on Myocardial Revascularization the Task Force on Myocardial Revascularization of the European Society of Cardiology (esc) and the European Association for Cardio-thoracic Surgery (eacts) Developed with the Special Contribution of the European Association for Percutaneous Cardiovascular I , 2022 .
[18] Deepak L. Bhatt,et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. , 2010, Journal of the American College of Cardiology.
[19] S. Yusuf,et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. , 2010, The New England journal of medicine.
[20] G. Montalescot,et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. , 2010, Journal of the American College of Cardiology.
[21] Gregg W Stone,et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. , 2010, The New England journal of medicine.
[22] A. Kastrati,et al. Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement , 2010, Circulation.
[23] D. Tàssies,et al. Polymorphisms in platelet glycoproteins Ia and IIIa are associated with arterial thrombosis and carotid atherosclerosis in type 2 diabetes , 2010, Thrombosis and Haemostasis.
[24] Osamu Okazaki,et al. Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active Metabolite , 2010, Drug Metabolism and Disposition.
[25] J. Ferrières,et al. Genetic determinants of response to clopidogrel and cardiovascular events. , 2009, The New England journal of medicine.
[26] D. Angiolillo,et al. Pharmacogenetics in cardiovascular antithrombotic therapy. , 2009, Journal of the American College of Cardiology.
[27] J. O’Connell,et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. , 2009, JAMA.
[28] G. Montalescot,et al. Can we override clopidogrel resistance? , 2009, Circulation.
[29] F. Verheugt,et al. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. , 2009, Journal of the American College of Cardiology.
[30] G. Montalescot,et al. Cytochrome P450 2C19 polymorphism and clopidogrel after MI – Authors' reply , 2009, The Lancet.
[31] R. Rakhit,et al. Cytochrome P450 2C19 polymorphism and clopidogrel after MI , 2009, The Lancet.
[32] E. Antman,et al. Cytochrome p-450 polymorphisms and response to clopidogrel. , 2009, The New England journal of medicine.
[33] A. V. Van't Hof,et al. Long-Term Clinical Outcome After a First Angiographically Confirmed Coronary Stent Thrombosis: An Analysis of 431 Cases , 2009, Circulation.
[34] G. Montalescot,et al. Dose Effect of Clopidogrel Reloading in Patients Already on 75-mg Maintenance Dose: The Reload With Clopidogrel Before Coronary Angioplasty in Subjects Treated Long Term With Dual Antiplatelet Therapy (RELOAD) Study , 2008, Circulation.
[35] J. Tardif,et al. Clopidogrel 600-mg double loading dose achieves stronger platelet inhibition than conventional regimens: results from the PREPAIR randomized study. , 2008, Journal of the American College of Cardiology.
[36] Magnus Ingelman-Sundberg,et al. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. , 2007, Pharmacology & therapeutics.
[37] P. Serruys,et al. Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.
[38] Lippincott-Schwartz,et al. Supporting Online Material Materials and Methods Som Text Figs. S1 to S8 Table S1 Movies S1 to S3 a " Silent " Polymorphism in the Mdr1 Gene Changes Substrate Specificity Corrected 30 November 2007; See Last Page , 2022 .
[39] N. Kleiman,et al. Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel. , 2007, Thrombosis research.
[40] A. Kastrati,et al. Impact of P‐glycoprotein on clopidogrel absorption , 2006, Clinical pharmacology and therapeutics.
[41] Yibo Wang,et al. VKORC1 Haplotypes Are Associated With Arterial Vascular Diseases (Stroke, Coronary Heart Disease, and Aortic Dissection) , 2006, Circulation.
[42] P. Binkley,et al. Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination. , 2006, Journal of the American College of Cardiology.
[43] E. Trabetti,et al. PlA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation , 2004, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[44] Petra Verhoef,et al. MTHFR 677C-->T polymorphism and risk of coronary heart disease: a meta-analysis. , 2002, JAMA.
[45] E. DeLong,et al. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.